Chronotherapy Versus Conventional BP Control to Correct Abnormal Circadian BP Pattern in Kidney Transplant Recipients

Sponsor
Mayo Clinic (Other)
Overall Status
Completed
CT.gov ID
NCT01093703
Collaborator
(none)
99
1
2
47
2.1

Study Details

Study Description

Brief Summary

The purpose of this study is to identify and manage factors related to blood pressure control that impact organ function and survival in kidney transplant recipients. Loss of the circadian (relating to a 24-hour rhythm) blood pressure pattern is common in kidney transplant recipients and is associated with poor allograft kidney function. It is still unclear if restoring the normal day-night blood pressure (BP) pattern will translate into better allograft outcome. Although studies in patients with and without chronic kidney disease indicate that restoration of the normal nocturnal (night) dipping in BP is possible by changing the timing of the BP medications to cover the overnight period (chronotherapy), this has not been tested in kidney transplant patients.

Condition or Disease Intervention/Treatment Phase
  • Other: Medication Adjustment
N/A

Detailed Description

The challenge in kidney transplantation is to identify and manage factors that impact allograft function and survival. Loss of the circadian blood pressure pattern is common in kidney transplant recipients and is associated with poor allograft kidney function. Nevertheless, it is unclear if restoring the normal day-night BP pattern will translate into better allograft outcome. Although studies in patients with and without chronic kidney disease indicate that restoration of the normal nocturnal dipping in BP is possible by changing the timing of the BP medications to cover the overnight period (chronotherapy), this has not been tested in kidney transplant patients. This exploratory study is driven by the hypothesis that chronotherapy will restore the normal circadian BP pattern and will translate into better allograft function and into lower LVM 1-year from transplantation.

Study Design

Study Type:
Interventional
Actual Enrollment :
99 participants
Allocation:
Randomized
Intervention Model:
Factorial Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Randomized Trial to Explore the Effect of Chronotherapy Versus Conventional BP Control to Correct Abnormal Circadian BP Pattern and Improve Allograft Function in Kidney Transplant Recipients
Study Start Date :
Dec 1, 2008
Actual Primary Completion Date :
Nov 1, 2012
Actual Study Completion Date :
Nov 1, 2012

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Conventional Therapy

In the conventional therapy group, no medication changes other than the ones needed to achieve target awake average SBP will be undertaken. Time at which patients are taking their BP medications will be recorded.

Active Comparator: Intensive Therapy

In the intensive therapy group, BP medications will be adjusted to both control awake average systolic BP to target and to cover the overnight period in an attempt to control nocturnal hypertension.

Other: Medication Adjustment
Awake SBP≤135/85mmHg and patient is on once daily medications: Switch BP medications to pm period. Awake SBP SBP≤135/85mmHg and patient is on bid medications (e.g. metoprolol bid): Increase pm dose of the medication. If medication is already is at maximal dose or there is contraindication for increasing the dose (e.g. bradycardia), add another BP medicine in the evening time. Awake SBP≤135/85mmHg and patient is not on anti-hypertensive medications: Add BP medication at the pm period. Awake SBP>135/85mmHg: increase dose of antihypertensive medications or add more medications. All medications to be given in the evening time.

Outcome Measures

Primary Outcome Measures

  1. Percent drop in mean SBP at night-time compared to mean SBP in day-time [1 year]

  2. Glomerular filtration rate [1 year]

Secondary Outcome Measures

  1. Awake mean SBP [1 year]

  2. Presence of abnormal circadian BP pattern in recipients on steroid free and CIN free IS [1 year]

  3. Change in LVM [1 year]

  4. Urinary microalbumin excretion [4 months & 1 year]

  5. Long term renal function [2 years]

  6. Cardiovascular events (stroke, heart failure, myocardial infarction) [2 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Recipient of a kidney transplant.

  • Age≥18 years.

  • Stable allograft function.

  • Ability to give informed consent.

Exclusion Criteria:
  • Multiorgan transplant recipients.

  • Kidney transplant recipients with poor allograft function.

  • Documented history of obstructive sleep apnea.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mayo Clinic Jacksonville Florida United States 32224

Sponsors and Collaborators

  • Mayo Clinic

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Hani M. Wadei, Cons-Nephrology, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT01093703
Other Study ID Numbers:
  • 08-005049
First Posted:
Mar 26, 2010
Last Update Posted:
May 30, 2013
Last Verified:
May 1, 2013
Keywords provided by Hani M. Wadei, Cons-Nephrology, Mayo Clinic

Study Results

No Results Posted as of May 30, 2013